Bishop EJ, et al. - A retrospective observational study at a metropolitan university-affiliated hospital was conducted to assess the efficacy and adverse effects correlated with tigecycline combination therapy for severe and severe-complicated Clostridium difficile infection (CDI) in an Australian healthcare setting. Between February 2013 and October 2016, subjects treated with adjunctive intravenous tigecycline for > 48 hours for severe or severe-complicated CDI were involved. It was observed that tigecycline appeared harmless and effective as a part of combination therapy in severe CDI. Researchers suggested that tigecycline could be given earlier and for shorter durations than in current guidelines.